Meclofenamic acid
| Clinical data | |
|---|---|
| Trade names | Meclomen |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | By mouth |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.010.382 |
| Chemical and physical data | |
| Formula | C14H11Cl2NO2 |
| Molar mass | 296.15 g·mol−1 |
Meclofenamic acid (used as meclofenamate sodium, brand name Meclomen) is a drug used for joint, muscular pain, arthritis and dysmenorrhea. It is a member of the anthranilic acid derivatives (or fenamate) class of nonsteroidal anti-inflammatory drugs (NSAIDs) and was approved by the US FDA in 1980. Like other members of the class, it is a cyclooxygenase (COX) inhibitor, preventing the formation of prostaglandins.
Scientists led by Claude Winder from Parke-Davis invented meclofenamate sodium in 1964, along with fellow members of the class, mefenamic acid in 1961 and flufenamic acid in 1963.: 718
Patents on the drug expired in 1985: 295 and several generics were introduced in the US, but as of July 2015 only Mylan still sold it.
It is not widely used in humans as it has a high rate (30-60%) rate of gastrointestinal side effects.: 310